![]() |
市場調査レポート
商品コード
1541016
ウシ胎仔血清市場レポート:製品、用途、エンドユーザー、地域別 2024-2032Fetal Bovine Serum Market Report by Product, Application, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
ウシ胎仔血清市場レポート:製品、用途、エンドユーザー、地域別 2024-2032 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2~3営業日
|
ウシ胎仔血清市場の世界市場規模は、2023年に10億340万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに15億9,240万米ドルに達し、2024年から2032年の間に5.1%の成長率(CAGR)を示すと予測しています。
ウシ胎仔血清(FBS)は動物細胞培養培地の主要成分で、牛の胎児から得られます。FBSには、細胞の成長に不可欠ないくつかの栄養因子と高分子因子が含まれています。これに加えて、アミノ酸、糖、脂質、ホルモン、低ガンマグロブリン含量も含んでいます。その結果、必須栄養素の供給や真核細胞培養における細胞の生存と増殖の促進など、さまざまな用途に広く利用されています。また、研究、製造、バイオ医薬品、ヒトおよび動物用ワクチンの管理にも使用されています。
FBSは、コロナウイルス感染症(COVID-19)による急性および慢性の肺障害を患う患者の治療用幹細胞の作製に応用されています。さらに、FBSには成長因子や抗体が含まれており、細胞を分裂、成長、進化させるために生かすことができるため、様々な科学研究において極めて重要な役割を果たしています。このことは、新規バイオ医薬品を導入するための政府機関や民間機関による資金提供の増加による研究開発(R&D)活動の著しい成長とともに、世界のFBSの需要を刺激しています。さらに、急性および慢性疾患の有病率の増加を背景としたバイオ医薬品に対する需要の高まりも、市場の成長に寄与しています。これとは別に、核家族化と所得水準の上昇という新たな動向は、ペットの所有と人間化にプラスの影響を与えており、その結果、コンパニオンアニマルの導入が世界中で増加しています。このことは、動物由来製品の消費量の増加とともに、世界中の感染症予防のための動物用診断薬およびワクチンにおけるFBSの必要性を煽ると予想されます。
The global fetal bovine serum market size reached US$ 1,003.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,592.4 Million by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Fetal bovine serum (FBS) is a major component of animal cell culture media, which is obtained from bovine fetuses of cows. It has several nutritional and macromolecular factors that are essential for cell growth. Besides this, it also comprises amino acids, sugars, lipids, hormones, and low gamma globulin content. As a result, it is widely utilized in a range of applications, such as providing essential nutrients and facilitating cell survival and proliferation in eukaryotic cell culture. It is also used in research, manufacturing, biotech drugs, and controlling human and veterinary vaccines.
FBS finds application in generating stem cells for treating patients suffering from acute and chronic lung damage due to coronavirus disease (COVID-19). In addition, as it contains growth factors and antibodies that can be utilized in laboratories to keep cells alive for dividing, growing, and evolving, it plays a pivotal role in various scientific research. This, along with significant growth in the research and development (R&D) activities on account of increasing funding by governing and private agencies to introduce novel biopharmaceuticals, is catalyzing the demand for FBS worldwide. Furthermore, the escalating demand for biopharma products on account of the growing prevalence of acute and chronic diseases is contributing to the growth of the market. Apart from this, the emerging trend of nuclear families and inflating income levels are positively influencing pet ownership and humanization, which is resulting in the increasing adoption of companion animals across the globe. This, along with the rising consumption of animal-derived products, is anticipated to fuel the need for FBS in veterinary diagnostics and vaccines to prevent infectious diseases around the world.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fetal bovine serum market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end user.
Charcoal Stripped
Chromatographic
Dialyzed Fetal Bovine Serum
Exosome Depleted
Stem Cell
Others
Biopharmaceuticals
Cell Culture
Human and Animal Vaccine Production
Others
Biotechnology and Pharmaceutical Companies
Academic Institutes
Research Laboratories
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Atlas Biologicals Inc., Biological Industries (Sartorius AG), Bio-Techne Corporation, BioWest, Bovogen Biologicals Pty Ltd., General Electric Company, HiMedia Laboratories, Merck KGaA, PAN-Biotech, Rocky Mountain Biologicals, TCS Biosciences Ltd and Thermo Fisher Scientific Inc.